The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia

Cardiovascular Therapeutics

Volumn 32, Issue 2, 2014, Pages 40-46

  Krysiak, Robert ^a   Zmuda, Witold ^b   Okopien, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Invasive Cardiology Electrotherapy and Angiology Centre   (Poland)

Author keywords

Adiponectin; Ezetimibe; Hypercholesterolemia; Leptin; Statins; Tumor necrosis factor (TNF ); Visfatin

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN; C REACTIVE PROTEIN; EZETIMIBE; FATTY ACID; INSULIN; LEPTIN; LIPID; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLACEBO; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL;

ADIPONECTIN; EZETIMIBE; HYPERCHOLESTEROLEMIA; LEPTIN; STATINS; TUMOR NECROSIS FACTOR-Α (TNF-Α); VISFATIN;

ADIPOKINES; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; RISK REDUCTION BEHAVIOR; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896100370     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12057     Document Type: Article

References (26)

1. Dembowski E, Davidson MH. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev 2009;29:2-12.
2. Schaefer JR. Lipid management for the prevention of cardiovascular disease. Curr Pharm Des 2011;17:852-860.
3. Koch CG. Statin therapy. Curr Pharm Des 2012;18:6284-6290.
4. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009;15:490-516.
5. Miura S, Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med 2008;47:1165-1170.
6. Meaney A, Ceballos G, Asbun J, Solache G, Mendoza E, Vela A, Meaney E. The Vytorin on carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-847.
7. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-2205.
8. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443.
9. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-2122.
10. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356.
11. Krysiak R, Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol 2011;57:505-512.
12. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 2012;271:32-42.
13. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundam Clin Pharmacol 2012;26:424-431.
14. Krysiak R, Labuzek K, Okopien B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep 2009;61:1134-1145.
15. Labuzek K, Buldak L, Dulawa-Buldak A, Bielecka A, Krysiak R, Madej A, Okopien B. Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia. Pharmacol Rep 2011;63:1124-1136.
16. Ahima RS, Osei SY. Adipokines in obesity. Front Horm Res 2008;36:182-197.
17. Calabro P, Yeh ET. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep 2008;10:32-38.
18. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol 2006;98:2P-8P.
19. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007;65(12 Pt 2):S253-S259.
20. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29:2959-2971.
21. Smith CC, Yellon DM. Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 2011;129:206-219.
22. Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011;107:1010-1018.
23. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009;7(Suppl 1):328-331.
24. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol 2012;57:91-97.
25. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-751.
26. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507:357-361.